CELC

CELC

Celcuity LLC

Rev โ€”top 1%5Y
Hold

Celcuity LLC develops targeted therapies for solid tumors, focusing on advanced breast cancer and metastatic castration-resistant prostate cancer. Its lead drug, Gedatolisib, inhibits the PI3K/mTOR pathway and is in clinical trials for various indications.

โš•๏ธ Healthcare NASDAQ Listed 2017 $ USD
$1,000 invested 5 years ago โ†’$4,206today

Score Overview

1 Year
Score
Net Growth-8.95%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth0.00%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth-4x
Net TrendNever
Net Income Consistencyโ€”
Rev Growthโ€”
Rev Trend20%
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-28x
Net Trend11%
Net Income Consistency
Rev Growthโ€”
Rev Trend11%
Revenue Consistency

See the full market ranking โ†’

Celcuity LLC fundamental performance

Across Celcuity LLC's full reported history, from 2017 to 2025, revenue grew from $ 0.00 to $ 154K and net income went from -$ 6M to -$ 177M. Revenue increased in 11% of the years measured; net income in 11%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 92.08โ€”
1 Year2025-08-12
$ 50.0683.94%
5 Years2021-08-12
$ 21.89320.65%
All Time2017-09-20
$ 14.296x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 154K-$ 192M$ 145M
2025$ 154K-$ 177M$ 441M
2024$ 0.00-$ 111M$ 235M
2023$ 0.00-$ 63M$ 180M
2022$ 0.00-$ 40M$ 168M
2021$ 0.00-$ 29M$ 84M
2020$ 0.00-$ 9M$ 11M
2019$ 0.00-$ 7M$ 18M
2018$ 0.00-$ 7M$ 24M
IPO2017$ 0.00-$ 6M$ 24M

Explore beyond CELC

You're looking at Celcuity LLC. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies